Aflibercept

Therapeutic Group

Neovascular (wet) Age-related Macular Degeneration:

By Intravitreal Inj:

Adult: Initially 2 Mg Once A Month For 3 Months, Then 2 Mg Every 2 Months, Review Treatment Frequency After 12 Months

Macular Oedema Secondary To Retinal Vein Occlusion:

By Intravitreal Inj:

Adult: Initially 2 Mg Once A Month Until Maximum Visual Acuity Is Achieved Or There Are No Signs Of Disease Activity (discontinue Treatment If No Improvement In Visual And Anatomic Outcomes)

Diabetic Macular Oedema:

By Intravitreal Inj:

Adult: Initially 2 Mg Once A Month For 5 Months, Then Maintenance 2 Mg Every 2 Months, Review Treatment Frequency After 12 Months (discontinue Treatment If No Improvement In Visual And Anatomic Outcomes)

Myopic Choroidal Neovascularisation:

By Intravitreal Inj:

Adult: 2 Mg For 1 Dose, If Visual Or Anatomic Outcomes Indicate That Disease Persists, Additional Doses May Be Administered; The Interval Between 2 Doses Should Be Greater Than 1 Month

Avoid Unless Potential Benefit Outweighs Risk

Ocular Or Periocular Infection, Severe Intra-ocular Inflammation, Irreversible Ischaemic Visual Function Loss Cautions: Diabetic Patients With Uncontrolled Hypertension, Active Systemic Infection, Discontinue Treatment If Stage 3 Or 4 Macular Holes Develop Or In The Event Of A Retinal Break Or Rhegmatogenous Retinal Detachment (consult Product Literature For Full Details), Patients At Risk Of Retinal Pigment Epithelial Tear, Poorly Controlled Glaucoma.

Ocular Or Periocular Infection, Severe Intra-ocular Inflammation, Irreversible Ischaemic Visual Function Loss Cautions: Diabetic Patients With Uncontrolled Hypertension, Active Systemic Infection, Discontinue Treatment If Stage 3 Or 4 Macular Holes Develop Or In The Event Of A Retinal Break Or Rhegmatogenous Retinal Detachment (consult Product Literature For Full Details), Patients At Risk Of Retinal Pigment Epithelial Tear, Poorly Controlled Glaucoma.